P27.10.B FACTORS INFLUENCING TIMELY DIAGNOSIS IN NEUROLYMPHOMATOSIS
Doubrovinskaia S, Egert A, Karschnia P, Scheffler G, Huttner A, Fulbright R, Baehring J, Kaulen L. P27.10.B FACTORS INFLUENCING TIMELY DIAGNOSIS IN NEUROLYMPHOMATOSIS. Neuro-Oncology 2024, 26: v138-v139. PMCID: PMC11485484, DOI: 10.1093/neuonc/noae144.472.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaPeripheral nervous systemNerve root lesionsDiagnostic intervalRelapse of NHLSymptom onsetAssociated with early diagnosisTertiary referral centerAtypical clinical presentationRoot lesionsCerebrospinal fluid examinationDiagnostic work-upYale Cancer CenterPainful polyneuropathyAsymmetric neuropathyClinical presentationReferral centerFluid examinationQuality control databaseDiagnostic delayFDG-PETPrimary diseaseUnivariate analysisConventional CTNeurolymphomatosisFactors influencing timely diagnosis in neurolymphomatosis
Doubrovinskaia S, Egert A, Karschnia P, Scheffler G, Traub B, Galluzzo D, Huttner A, Fulbright R, Baehring J, Kaulen L. Factors influencing timely diagnosis in neurolymphomatosis. Journal Of Neuro-Oncology 2024, 170: 1-9. PMID: 39115616, DOI: 10.1007/s11060-024-04792-2.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaPeripheral nervous systemDiagnostic intervalNon-Hodgkin lymphoma diagnosisSymptom onset to diagnosisCerebrospinal fluid examinationYale Cancer CenterPainful polyneuropathyAsymmetric neuropathyRare entityMedian intervalFluid examinationQuality control databaseDelayed diagnosisPrimary diseaseUnivariate analysisConventional CTDisease sitesNeurolymphomatosisNeuro-oncologyCancer CenterSecondary diseaseImaging modalitiesNeuroimaging findingsDiagnosisClinical Presentation, Management, and Outcome in Neurolymphomatosis
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. Clinical Presentation, Management, and Outcome in Neurolymphomatosis. Neurology 2024, 103: e209698. PMID: 39102613, DOI: 10.1212/wnl.0000000000209698.Peer-Reviewed Original ResearchConceptsPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETMedian overall survivalRituximab-based therapyRituximab-based treatmentNon-Hodgkin's lymphomaManifestation of malignancyNervous systemLog-rank testTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseIndividual patient dataProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratification